These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 35701876)

  • 1. Oral versus subcutaneous semaglutide for prevention of major adverse cardiovascular events: cost per outcome analysis of SUSTAIN-6 and PIONEER-6.
    Hammerman A; Moore CM; Aboalhasan E; Azuri J; Arbel R
    Postgrad Med; 2022 Sep; 134(7):654-658. PubMed ID: 35701876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk.
    Husain M; Bain SC; Jeppesen OK; Lingvay I; Sørrig R; Treppendahl MB; Vilsbøll T
    Diabetes Obes Metab; 2020 Mar; 22(3):442-451. PubMed ID: 31903692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Usefulness of Empagliflozin Versus Oral Semaglutide for Prevention of Cardiovascular Mortality in Patients With Type 2 Diabetes Mellitus.
    Hammerman A; Moore CM; Aboalhasan E; Azuri J; Arbel R
    Am J Cardiol; 2022 May; 170():128-131. PubMed ID: 35197207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials.
    Husain M; Bain SC; Holst AG; Mark T; Rasmussen S; Lingvay I
    Cardiovasc Diabetol; 2020 Sep; 19(1):156. PubMed ID: 32998732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes.
    Guzauskas GF; Rind DM; Fazioli K; Chapman RH; Pearson SD; Hansen RN
    J Manag Care Spec Pharm; 2021 Apr; 27(4):455-468. PubMed ID: 33769850
    [No Abstract]   [Full Text] [Related]  

  • 6. Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6.
    Nauck MA; Quast DR
    Front Endocrinol (Lausanne); 2021; 12():645566. PubMed ID: 33854484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials.
    Aroda VR; Ahmann A; Cariou B; Chow F; Davies MJ; Jódar E; Mehta R; Woo V; Lingvay I
    Diabetes Metab; 2019 Oct; 45(5):409-418. PubMed ID: 30615985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Will oral semaglutide be used to reduce cardiovascular risk in subjects with type 2 diabetes instead of subcutaneous semaglutide?
    Doggrell SA
    Expert Opin Biol Ther; 2020 May; 20(5):489-492. PubMed ID: 32005073
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide.
    Gallwitz B; Giorgino F
    Front Endocrinol (Lausanne); 2021; 12():645507. PubMed ID: 34267725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral semaglutide in patients with type 2 diabetes and cardiovascular disease, renal impairment, or other comorbidities, and in older patients.
    Mosenzon O; Miller EM; Warren ML
    Postgrad Med; 2020 Nov; 132(sup2):37-47. PubMed ID: 32815439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: A value for money analysis.
    Azuri J; Hammerman A; Aboalhasan E; Sluckis B; Arbel R
    Diabetes Obes Metab; 2023 Apr; 25(4):961-964. PubMed ID: 36507900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral Semaglutide: The First-available Noninjectable Glucagon-like Peptide 1 Receptor Agonist.
    Powell J; Piszczatoski C; Taylor JR
    Clin Ther; 2020 Oct; 42(10):2100-2116. PubMed ID: 32873415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimated Life-Years Gained Free of New or Recurrent Major Cardiovascular Events With the Addition of Semaglutide to Standard of Care in People With Type 2 Diabetes and High Cardiovascular Risk.
    Westerink J; Matthiessen KS; Nuhoho S; Fainberg U; Lyng Wolden M; Østergaard HB; Visseren F; Sattar N
    Diabetes Care; 2022 May; 45(5):1211-1218. PubMed ID: 35263432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes.
    Aroda VR; Erhan U; Jelnes P; Meier JJ; Abildlund MT; Pratley R; Vilsbøll T; Husain M
    Diabetes Obes Metab; 2023 May; 25(5):1385-1397. PubMed ID: 36700417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of Semaglutide.
    Smits MM; Van Raalte DH
    Front Endocrinol (Lausanne); 2021; 12():645563. PubMed ID: 34305810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.
    Pieber TR; Bode B; Mertens A; Cho YM; Christiansen E; Hertz CL; Wallenstein SOR; Buse JB;
    Lancet Diabetes Endocrinol; 2019 Jul; 7(7):528-539. PubMed ID: 31189520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6.
    Strain WD; Frenkel O; James MA; Leiter LA; Rasmussen S; Rothwell PM; Sejersten Ripa M; Truelsen TC; Husain M
    Stroke; 2022 Sep; 53(9):2749-2757. PubMed ID: 35582947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of oral semaglutide in managing type 2 diabetes in Indian clinical settings: Addressing the unmet needs.
    Joshi SR; Rajput R; Chowdhury S; Singh AK; Bantwal G; Das AK; Unnikrishnan AG; Saboo BD; Kesavadev J; Ghosal S; Mohan V
    Diabetes Metab Syndr; 2022 Jun; 16(6):102508. PubMed ID: 35653929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral Semaglutide: A Review of the First Oral Glucagon-Like Peptide 1 Receptor Agonist.
    Bucheit JD; Pamulapati LG; Carter N; Malloy K; Dixon DL; Sisson EM
    Diabetes Technol Ther; 2020 Jan; 22(1):10-18. PubMed ID: 31436480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy.
    Wright EE; Aroda VR
    Postgrad Med; 2020 Nov; 132(sup2):26-36. PubMed ID: 32815423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.